These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 23536478)
1. Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication. Qin X; Zhang H; Ye D; Yao X; Zhang S; Dai B Andrology; 2013 May; 1(3):512-6. PubMed ID: 23536478 [TBL] [Abstract][Full Text] [Related]
2. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136 [TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
4. Hormonal therapy of prostate cancer. Labrie F Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672 [TBL] [Abstract][Full Text] [Related]
5. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer. Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406 [TBL] [Abstract][Full Text] [Related]
6. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418 [TBL] [Abstract][Full Text] [Related]
8. Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer. Hashimoto K; Masumori N; Hashimoto J; Takayanagi A; Fukuta F; Tsukamoto T Jpn J Clin Oncol; 2011 Mar; 41(3):405-10. PubMed ID: 20947624 [TBL] [Abstract][Full Text] [Related]
9. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? Perachino M; Cavalli V; Bravi F BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358 [TBL] [Abstract][Full Text] [Related]
10. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137 [TBL] [Abstract][Full Text] [Related]
11. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer. Appu S; Lawrentschuk N; Grills RJ; Neerhut G J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599 [TBL] [Abstract][Full Text] [Related]
13. Innovative approaches to the hormonal treatment of advanced prostate cancer. Trachtenberg J Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer. Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918 [TBL] [Abstract][Full Text] [Related]
15. Role of testosterone in managing advanced prostate cancer. Rove KO; Debruyne FM; Djavan B; Gomella LG; Koul HK; Lucia MS; Petrylak DP; Shore ND; Stone NN; Crawford ED Urology; 2012 Oct; 80(4):754-62. PubMed ID: 22795376 [TBL] [Abstract][Full Text] [Related]
16. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? Mottet N; Lucas C; Sene E; Avances C; Maubach L; Wolff JM Urol Int; 2005; 75(3):204-8. PubMed ID: 16215305 [TBL] [Abstract][Full Text] [Related]
17. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer. Kobayashi T; Nishizawa K; Mitsumori K Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259 [TBL] [Abstract][Full Text] [Related]
18. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Tunn UW; Canepa G; Kochanowsky A; Kienle E Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):296-302. PubMed ID: 22733160 [TBL] [Abstract][Full Text] [Related]
19. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. Morote J; Planas J; Salvador C; Raventós CX; Catalán R; Reventós J BJU Int; 2009 Feb; 103(3):332-5; discussion 335. PubMed ID: 19007366 [TBL] [Abstract][Full Text] [Related]
20. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. Garnick MB; Mottet N BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]